Opportunity Information: Apply for PA 15 039
Apply for PA 15 039
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Diabetes and Cardiovascular Disease in Older Adults (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Nov 19, 2014 and posted on Nov 18, 2014.
- Applicants must submit their applications by Jan 7, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $100,000.00 in funding.
- Eligible applicants include: Small businesses Native American tribal organizations (other than Federally recognized tribal governments) State governments Special district governments Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses City or township governments Public and State controlled institutions of higher education Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) funding opportunity "Diabetes and Cardiovascular Disease in Older Adults (R03)" (Funding Opportunity Number PA-15-039) supports small, focused research projects that examine how aging influences the development of diabetes mellitus (DM), the diagnosis and clinical management of diabetes in later life, and the cardiovascular disease (CVD) complications that often accompany diabetes in older people. The FOA is designed to encourage basic, clinical, and epidemiological or outcomes-oriented studies that can clarify why older adults are more vulnerable to diabetes and diabetes-related cardiovascular problems, and to generate evidence that can improve real-world care decisions for this population. Studies may involve older human participants, relevant animal models, or both, as long as the central question relates to aging and its relationship to diabetes and CVD outcomes.
A major emphasis of the announcement is understanding the changing burden of diabetes with advancing age, including the patterns of increasing incidence and prevalence among older adults. The FOA specifically highlights the importance of epidemiological work that can explain who is most affected, how trends are shifting over time, and whether there are racial or ethnic disparities in risk, diagnosis, treatment, or outcomes. Projects in this area could include population-based analyses, cohort studies, secondary analyses of existing datasets, or other approaches that identify high-risk subgroups and clarify where disparities emerge across the lifespan into older age.
Another core priority is identifying the biological and physiological mechanisms of aging that predispose older adults to developing diabetes and, in turn, diabetes-associated cardiovascular complications. This includes research aimed at teasing apart age-related changes that may alter glucose regulation, insulin sensitivity, inflammation, vascular function, cardiac structure, lipid metabolism, or other pathways that connect diabetes to cardiovascular injury. By focusing on mechanisms that are specifically age-related, the FOA encourages work that goes beyond general diabetes or CVD biology and instead explains what is distinct about disease onset and progression in older bodies.
The FOA also calls for research that explains why older adults with diabetes often experience higher incidence and greater severity of cardiovascular outcomes. This can include studies of heart disease, stroke, vascular complications, and other CVD endpoints, with attention to how aging changes risk profiles, symptom presentation, disease trajectories, and responses to treatment. The goal is to develop clearer evidence on the interaction between age, diabetes, and cardiovascular pathology, including how age might intensify complications or change the kinds of complications that are most likely to occur.
In addition, the opportunity strongly encourages work that leads to age-specific approaches to prevention, screening, diagnosis, and management of diabetes and its cardiovascular complications. This reflects the practical challenge that older adults are not simply "older versions" of younger patients; they often have different baseline risks, comorbidities, functional status considerations, medication tolerability issues, and competing health priorities. Research responsive to this part of the FOA could evaluate or refine screening and diagnostic strategies appropriate for older adults, improve risk stratification methods, or test interventions and management approaches that better match older patients needs. The expected payoff is evidence-based guidance that can inform more appropriate diagnostic criteria, better prediction of who is most at risk for poor outcomes, and improved recommendations to prevent diabetes onset or reduce short- and long-term complications, particularly cardiovascular ones.
From an administrative and eligibility standpoint, this is a discretionary NIH grant using the R03 mechanism, which is typically used for smaller, shorter projects that can generate targeted findings, pilot data, or proof-of-concept results. The award ceiling listed is $100,000, and there is no cost-sharing or matching requirement. Eligible applicants are broad and include public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) organizations), for-profit organizations (including small businesses), and a wide range of government entities (state, county, city/township, special district, and certain tribal governments). The FOA also allows non-U.S. (foreign) organizations and foreign components under NIH policy, along with U.S. territories or possessions and various minority-serving institutions (such as HBCUs, Hispanic-serving institutions, and tribally controlled colleges and universities), as well as faith-based or community-based organizations, and eligible federal agencies.
Key dates show the FOA was posted in November 2014, with the original and current closing date listed as January 7, 2018, and an archive date of February 7, 2018. The CFDA number associated with the opportunity is 93.866 (Aging Research). The full announcement was available through the NIH grants guide at the link provided in the source, and the NIH Office of Extramural Research (OER) webmaster contact is listed for access or technical issues related to the posting.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The funding opportunity is titled "Diabetes and Cardiovascular Disease in Older Adults (R03)."
What is the Funding Opportunity Number (FOA number)?
The FOA number is PA-15-039.
What is the main purpose of this FOA?
This FOA supports small, focused research projects that examine how aging influences (1) the development of diabetes mellitus (DM), (2) the diagnosis and clinical management of diabetes in later life, and (3) the cardiovascular disease (CVD) complications that often accompany diabetes in older adults.
What kinds of research does the FOA encourage?
The FOA is designed to encourage basic, clinical, and epidemiological or outcomes-oriented studies that help clarify why older adults are more vulnerable to diabetes and diabetes-related cardiovascular problems, and that generate evidence to improve real-world care decisions for older people.
Is this opportunity focused specifically on older adults?
Yes. The central theme is aging and its relationship to diabetes and cardiovascular disease outcomes in older adults, including how disease onset, progression, complications, and management may differ in later life.
Do proposed studies have to include human participants?
No. Studies may involve older human participants, relevant animal models, or both, as long as the central research question relates to aging and its relationship to diabetes and CVD outcomes.
What diabetes-related topics in aging are emphasized?
The FOA emphasizes understanding how aging influences diabetes burden, mechanisms that predispose older adults to diabetes, and the clinical realities of diagnosing and managing diabetes in later life.
What cardiovascular disease (CVD) topics are emphasized?
The FOA highlights research on diabetes-associated cardiovascular complications in older adults, including why older adults with diabetes often have higher incidence and greater severity of cardiovascular outcomes (such as heart disease, stroke, and vascular complications), and how aging changes risk profiles, symptom presentation, disease trajectories, and responses to treatment.
Does the FOA prioritize epidemiological research?
Yes. A major emphasis is understanding the changing burden of diabetes with advancing age, including patterns of increasing incidence and prevalence among older adults, shifting trends over time, and identifying who is most affected.
Are racial or ethnic disparities part of the scope?
Yes. The FOA specifically highlights the importance of work that examines whether there are racial or ethnic disparities in risk, diagnosis, treatment, or outcomes for diabetes and related cardiovascular complications as people age.
What types of epidemiological approaches are mentioned as responsive?
Examples described include population-based analyses, cohort studies, secondary analyses of existing datasets, and other approaches that identify high-risk subgroups and clarify where disparities emerge across the lifespan into older age.
Does the FOA support mechanistic or biological research related to aging?
Yes. Another core priority is identifying the biological and physiological mechanisms of aging that predispose older adults to developing diabetes and diabetes-associated cardiovascular complications.
What kinds of age-related mechanisms are within scope?
The FOA lists examples such as age-related changes in glucose regulation, insulin sensitivity, inflammation, vascular function, cardiac structure, lipid metabolism, and other pathways that connect diabetes to cardiovascular injury, with emphasis on what is distinct about disease onset and progression in older bodies.
Is the FOA interested in how aging changes clinical presentation or treatment response?
Yes. The FOA calls for research on how aging affects risk profiles, symptom presentation, disease trajectories, and responses to treatment for cardiovascular outcomes in older adults with diabetes.
Does the FOA encourage work on prevention, screening, or diagnosis tailored to older adults?
Yes. The opportunity strongly encourages research that leads to age-specific approaches to prevention, screening, diagnosis, and management of diabetes and its cardiovascular complications.
Why does the FOA emphasize age-specific approaches rather than applying younger-adult strategies?
The FOA notes that older adults are not simply "older versions" of younger patients. Older adults often differ in baseline risks, comorbidities, functional status considerations, medication tolerability issues, and competing health priorities, which can affect screening, diagnosis, and management decisions.
What kinds of practical or clinical deliverables does NIH appear to want from this research?
The FOA describes an expected payoff of evidence that can inform more appropriate diagnostic criteria, better prediction and risk stratification for poor outcomes, and improved recommendations to prevent diabetes onset or reduce short- and long-term complications, particularly cardiovascular ones, in older adults.
What NIH grant mechanism is used for this opportunity?
This is an NIH discretionary grant using the R03 mechanism.
What does the R03 mechanism imply about project size and scope?
The FOA describes the R03 as typically supporting smaller, shorter projects intended to generate targeted findings, pilot data, or proof-of-concept results.
What is the award ceiling for this opportunity?
The award ceiling listed is $100,000.
Is cost-sharing or matching required?
No. The FOA states there is no cost-sharing or matching requirement.
Which organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofits (including 501(c)(3) and non-501(c)(3)); for-profit organizations (including small businesses); and many government entities (including state, county, city/township, special district, and certain tribal governments). The FOA also includes U.S. territories or possessions and various minority-serving institutions, along with faith-based or community-based organizations and eligible federal agencies.
Are minority-serving institutions explicitly included?
Yes. The FOA lists minority-serving institutions such as HBCUs, Hispanic-serving institutions, and tribally controlled colleges and universities as eligible applicants.
Are non-U.S. (foreign) organizations allowed to apply?
Yes. The FOA indicates non-U.S. (foreign) organizations and foreign components are allowed under NIH policy.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.866 (Aging Research).
When was the FOA posted?
The FOA was posted in November 2014.
What were the key closing and archival dates?
The original and current closing date is listed as January 7, 2018, and the archive date is February 7, 2018.
Where was the full announcement available?
The full announcement was available through the NIH grants guide at the link referenced in the source information.
Who is listed as a contact for access or technical issues related to the posting?
The NIH Office of Extramural Research (OER) webmaster contact is listed for access or technical issues related to the posting.
Does the FOA limit research to diabetes alone, or is cardiovascular disease required?
The FOA centers on diabetes in older adults and the cardiovascular disease complications that often accompany diabetes. It supports research that examines aging in relation to diabetes and/or diabetes-associated cardiovascular outcomes, with strong emphasis on clarifying the diabetes-CVD connection in later life.
Can projects focus on real-world clinical decision-making for older adults with diabetes?
Yes. The FOA explicitly aims to generate evidence that can improve real-world care decisions for older adults, including work that refines screening, diagnostic strategies, risk stratification, or management approaches appropriate for older patients.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Research Aimed at Novel Behavioral Targets to Improve Adolescent Substance Abuse Treatment and Prevention Interventions (R01)
Previous opportunity: Diabetes and Cardiovascular Disease in Older Adults (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 15 039
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 15 039) also looked into and applied for these:
| Funding Opportunity |
|---|
| Targeting Persistent HIV Reservoirs (TaPHIR) (R21/R33) Apply for PAR 15 041 Funding Number: PAR 15 041 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Administrative Supplements for Tobacco Regulatory Research on the Public Display of Harmful and Potentially Harmful Constituents (HPHC) Information (Admin Supp) Apply for PA 15 046 Funding Number: PA 15 046 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Family and Interpersonal Relationships in an Aging Context (R01) Apply for PA 15 042 Funding Number: PA 15 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Career Transition Award for Nurturing Clinician Investigators (K22) Apply for RFA DC 15 002 Funding Number: RFA DC 15 002 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Service Area Competition Additional Area (SAC AA) Dayton, OH Apply for HRSA 15 131 Funding Number: HRSA 15 131 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,104,448 |
| Local Capacity Initiative Program Apply for RFA 517 14 000006 Funding Number: RFA 517 14 000006 Agency: Dominican Republic USAID Santo Domingo Category: Health Funding Amount: $500,000 |
| Support for Orphans and Vulnerable Children in Nairobi and Coast Counties of Kenya Apply for RFA 615 14 000006 Funding Number: RFA 615 14 000006 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $42,000,000 |
| Lab to Marketplace Tools for Biomedical and Behavioral Research (R43/R44) Apply for PA 15 052 Funding Number: PA 15 052 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Underactive Bladder in Aging (R03) Apply for PA 15 050 Funding Number: PA 15 050 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Underactive Bladder in Aging (R21) Apply for PA 15 051 Funding Number: PA 15 051 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| PPHF 2015 Preventive Health and Health Services Block Grants Behavioral Risk Factor Surveillance System (Pacific Jurisdictions) Financed in Part by 2015 Prevention and Public Health Funds Apply for CDC RFA DP15 1513 Funding Number: CDC RFA DP15 1513 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Alzheimers Disease Sequencing Project (ADSP) Replication Phase Analysis Studies (U01) Apply for RFA AG 16 002 Funding Number: RFA AG 16 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| NIA Coordinating Center for Genetics and Genomics of Alzheimers Disease (U54) Apply for RFA AG 16 001 Funding Number: RFA AG 16 001 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) Apply for RFA HL 16 006 Funding Number: RFA HL 16 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sickle Cell Disease Newborn Screening Program Apply for HRSA 15 078 Funding Number: HRSA 15 078 Agency: Health Resources and Services Administration Category: Health Funding Amount: $2,679,000 |
| Alcohol Education Project Grants (R25) Apply for PAR 15 054 Funding Number: PAR 15 054 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Innovative Measures of Oral Medication Adherence for HIV Treatment and Prevention (R01) Apply for RFA AI 14 071 Funding Number: RFA AI 14 071 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Evaluation Capacity within the Government of Tanzania under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1589 Funding Number: CDC RFA GH15 1589 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,500,000 |
| Partnering with Pasteur Institute of Ho Chi Minh City to Enhance Regional Capacity to Prevent, Detect, Monitor, and Respond to the HIV/AIDS Epidemic in Vietnam under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1595 Funding Number: CDC RFA GH15 1595 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $4,000,000 |
| Statewide Family Network Program Apply for SM 15 001 Funding Number: SM 15 001 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $95,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 15 039", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.